Archive: Company News

Captain T Cell Secures Seed Financing Round Totaling € 8.5 Million

— i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH and HIL-INVENT Ges.m.b.H. participated in the seed round

— Funds will be used to accelerate a new generation of T cell therapies against solid tumors towards the clinic

Schoenefeld/Berlin, Germany, May 22, 2024Captain T Cell GmbH, a biotechnology company developing next-generation T cells against solid tumors, today announced the successful closing of a seed financing round totaling € 8.5 million. A syndicate of experienced life science investors including i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH, and HIL-INVENT Ges.m.b.H participated in the round. In addition, the German Federal Ministry of Education and Research (BMBF) is supporting the Company through its prestigious GO-Bio program. The financing also marks the appointment of biotech veteran Jörn Aldag as Chairman of the Board of Directors.

Read more…

Atopia Therapeutics, Formerly HpVac, Announces Appointment of Dr. Gregoire Chevalier as CEO and Business Update

Geneva (Switzerland), May 7, 2024 – Atopia Therapeutics, a leader in the development of breakthrough asthma and allergy therapies, today announced the appointment of Dr. Grégoire Chevalier as Chief Executive Officer (CEO). Formerly known as HpVac, the Company has repositioned itself under the new name Atopia Therapeutics to better reflect its commitment to addressing the growing global burden of atopic diseases.

Read more…

selectION Announces Positive Results from Phase 1b Clinical Trial Evaluating si-544 in Patients with Atopic Dermatitis

— si-544 was well tolerated with no serious adverse effects, dose limiting toxicities, or safety signals observed

— 75% of patients receiving si-544 experienced objective clinical improvement, of which 44% achieved clear or almost clear skin

selectION, Inc., a clinical-stage biopharmaceutical company developing novel treatments for T-cell mediated autoimmune diseases, today announced positive results from the first-in-human Phase 1b trial of its lead compound, si-544, in atopic dermatitis patients. si-544 is a selectivity-optimized peptide blocking the ion channel Kv1.3.

Read more…

Safer Travel to Africa Through Innovative Malaria Treatment

In an exciting advancement for international travel, DMG Deutsche Malaria GmbH, a pioneering Hamburg-based pharmaceutical company, is pleased to announce the development of a groundbreaking malaria treatment poised to significantly enhance travel safety to Africa. The treatment with its internal working title “MalaJic” (Malaria treatment Just In Case), represents a revolutionary step in standby healthcare for travellers to sub-Saharan Africa.

Read more…

1 2 162